EG24967A - New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them. - Google Patents

New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them.

Info

Publication number
EG24967A
EG24967A EG2004070320A EG2004070320A EG24967A EG 24967 A EG24967 A EG 24967A EG 2004070320 A EG2004070320 A EG 2004070320A EG 2004070320 A EG2004070320 A EG 2004070320A EG 24967 A EG24967 A EG 24967A
Authority
EG
Egypt
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
oxime compounds
new heterocyclic
Prior art date
Application number
EG2004070320A
Other languages
English (en)
Inventor
Veronique Leclerc
Sylvie Pailloux
Pascal Carato
Carine Introvigne
Nicolas Lebegue
Pascal Berthelot
Catherine Dacquet
Jean Albert Boutin
Daniel Henri Caignard
Pierre Renard
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of EG24967A publication Critical patent/EG24967A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EG2004070320A 2003-07-28 2004-07-28 New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them. EG24967A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0309214A FR2858321B1 (fr) 2003-07-28 2003-07-28 Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
EG24967A true EG24967A (en) 2011-03-13

Family

ID=33523001

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2004070320A EG24967A (en) 2003-07-28 2004-07-28 New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them.

Country Status (31)

Country Link
US (1) US7071221B2 (xx)
EP (1) EP1502590B1 (xx)
JP (1) JP4406331B2 (xx)
KR (1) KR100677013B1 (xx)
CN (1) CN100497323C (xx)
AR (1) AR045125A1 (xx)
AT (1) ATE348612T1 (xx)
AU (1) AU2004203454B2 (xx)
BR (1) BRPI0403028A (xx)
CA (1) CA2475137C (xx)
CY (1) CY1106336T1 (xx)
DE (1) DE602004003751T2 (xx)
DK (1) DK1502590T3 (xx)
EA (1) EA007718B1 (xx)
EG (1) EG24967A (xx)
ES (1) ES2279310T3 (xx)
FR (1) FR2858321B1 (xx)
GE (1) GEP20063896B (xx)
HK (1) HK1071748A1 (xx)
HR (1) HRP20070117T8 (xx)
MA (1) MA27104A1 (xx)
MX (1) MXPA04007257A (xx)
MY (1) MY139278A (xx)
NO (1) NO327257B1 (xx)
NZ (1) NZ534334A (xx)
PL (1) PL1502590T3 (xx)
PT (1) PT1502590E (xx)
SG (1) SG109010A1 (xx)
SI (1) SI1502590T1 (xx)
UA (1) UA80814C2 (xx)
ZA (1) ZA200405893B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957476A1 (en) * 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
FR2894965B1 (fr) * 2005-12-20 2008-01-25 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2898125B1 (fr) * 2006-03-06 2008-06-13 Servier Lab Nouveaux derives heterocycliques cycloalkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
FR2903404B1 (fr) * 2006-07-10 2008-08-22 Servier Lab Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
WO2012135615A2 (en) 2011-03-30 2012-10-04 Brown University Enopeptins, uses thereof, and methods of synthesis thereto
WO2016037072A2 (en) * 2014-09-04 2016-03-10 Brown University Enopeptin analogas and methods of use thereof
CN104788436B (zh) * 2015-03-13 2018-05-01 三峡大学 四氢苯并呋喃-4-酮肟基三唑药物，制备方法及其应用
CN104725367B (zh) * 2015-03-13 2017-06-23 三峡大学 四氢苯并噻唑‑7‑酮肟药物，制备方法及其应用
CN109996541A (zh) * 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32769A (en) * 1861-07-09 Beehive
US4228292A (en) * 1978-07-20 1980-10-14 Monsanto Company N-Substituted benzothiazolines and benzoxazolines and their use as herbicides and plant growth regulants
EP0022317B1 (en) * 1979-06-12 1983-09-21 Fujisawa Pharmaceutical Co., Ltd. 2-oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
SK111195A3 (en) * 1994-09-13 1997-06-04 Sandoz Technology Ltd Bicyclic ethers substituted with oxazole and thiazole, process for producing thereof and pharmaceutical composition containing same
FR2804431A1 (fr) * 2000-02-02 2001-08-03 Adir Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
FR2830012B1 (fr) * 2001-09-21 2003-10-31 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharamaceutiques qui les contiennent

Also Published As

Publication number Publication date
ZA200405893B (en) 2005-01-24
PL1502590T3 (pl) 2007-04-30
ATE348612T1 (de) 2007-01-15
CA2475137C (fr) 2010-04-06
MY139278A (en) 2009-09-30
FR2858321B1 (fr) 2006-01-20
DE602004003751D1 (de) 2007-02-01
DK1502590T3 (da) 2007-04-10
NO327257B1 (no) 2009-05-25
DE602004003751T2 (de) 2007-10-18
KR100677013B1 (ko) 2007-01-31
JP4406331B2 (ja) 2010-01-27
SG109010A1 (en) 2005-02-28
HRP20070117T3 (en) 2007-04-30
US7071221B2 (en) 2006-07-04
CY1106336T1 (el) 2011-10-12
CN100497323C (zh) 2009-06-10
US20050026973A1 (en) 2005-02-03
KR20050013514A (ko) 2005-02-04
MA27104A1 (fr) 2004-12-20
CN1590379A (zh) 2005-03-09
EP1502590B1 (fr) 2006-12-20
PT1502590E (pt) 2007-02-28
AR045125A1 (es) 2005-10-19
SI1502590T1 (sl) 2007-04-30
AU2004203454A1 (en) 2005-02-17
NZ534334A (en) 2005-12-23
EA200400867A2 (ru) 2005-02-24
EA007718B1 (ru) 2006-12-29
NO20043188L (no) 2005-01-31
EP1502590A1 (fr) 2005-02-02
JP2005047919A (ja) 2005-02-24
CA2475137A1 (fr) 2005-01-28
AU2004203454B2 (en) 2010-05-27
MXPA04007257A (es) 2005-03-31
BRPI0403028A (pt) 2005-06-14
UA80814C2 (en) 2007-11-12
GEP20063896B (en) 2006-08-10
EA200400867A3 (ru) 2005-04-28
ES2279310T3 (es) 2007-08-16
HK1071748A1 (en) 2005-07-29
FR2858321A1 (fr) 2005-02-04
HRP20070117T8 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
HK1071748A1 (en) New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them
EP1706412A4 (en) Novel pyridine derivatives, process for their preparation and pharmaceutical composition containing them
HUP0400208A3 (en) N-formyl hydroxylamine compounds, process for their preparation and pharmaceutical compositions containing them
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HK1096386A1 (en) Indanyl-piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
SG121999A1 (en) New benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200100864B (en) Piperidine-4-sulphonamides compounds, a process for their preparation and pharmaceutical compositions containing them.
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
ZA200302159B (en) New compounds derived from quinazoline, a process for their preparation and pharmaceutical compositions containing them.
HK1096097A1 (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
HK1049159A1 (en) New indenoindolone compounds, a process for their preparation and pharmaceutical compositions containing them.
ZA200402657B (en) Isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them.
SG113569A1 (en) New flourinated benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
HK1049000A1 (en) New isoindoloindolone compounds, a process for their preparation and pharmaceutical compositions containing them.
HK1070360A1 (en) Benzo ÄaÜpyranoÄ3,2-hÜacridin-7-one compounds, a process for their preparation and pharmaceutical compositions thereof
HK1050681A1 (en) New benzenesulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them.
ZA200501010B (en) BenzoÄBÜchromeno-naphthyridin-7-one and pyranoÄ2'3':7,8ÜquinoÄ2,3-BÜquinoxalin-7-one compounds, process for their preparation and pharmaceutical compositions containing them.
ZA200407444B (en) Benzoindoline Compounds, a process for their preparation and pharmaceutical compositions contained them.
HK1079775A1 (en) New 4-oxo-4,6,7,8-tetrahydro-pyrrolo Ä1,2-AÜpyrazine-6-carboxamide compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200800833B (en) New 1H-indole-pyridinecarboxamide and 1H-indolepiperidinecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200706249B (en) Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same
HK1098146A1 (en) New polysubstituted 1,1-pyridylaminocyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200103065B (en) Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds, a process for their preparation and pharmaceutical compositions containing them.
SG122000A1 (en) New benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200103064B (en) Cyclobutaindolecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them.